Director, Nonclinical Due Diligence & External Innovation

The position of Director, Nonclinical Due Diligence & External Innovation at CSL provides scientific oversight for evaluating pre‑clinical data that underpins licensing deals, acquisitions and collaborative projects. The role sits within the non‑clinical development function and contributes to strategic decisions across the company’s therapeutic portfolio. Day‑to‑day duties involve steering the complete due‑diligence workflow for assigned assets, from the initial request through to the final governance presentation. The incumbent gathers input from toxicology, pharmacokinetics/QSP, pharmacology and external specialists, synthesizes it into a unified risk narrative, and highlights gaps that could affect first‑in‑human studies, translational challenges or regulatory constraints. High‑quality reports, executive summaries and risk matrices are prepared for senior review, while serving as the scientific liaison between business development, therapeutic area teams and the non‑clinical organization. The role also supports selected research programs as the non‑clinical point of contact and helps refine due‑diligence templates and processes. Applicants must hold an advanced degree such as a Ph.D., D.V.M. or equivalent in toxicology, pharmacology or a related discipline, with a background in toxicology and preferably board certification. A minimum of ten years of experience in non‑clinical development, including substantial exposure to due‑diligence or external innovation across multiple regions, is required. Candidates need a solid grasp of first‑in‑human requirements for biologics and complex modalities, the ability to convey intricate scientific risk to non‑technical audiences, and fluency in written and spoken English. Strong planning, analytical, negotiation and cross‑functional teamwork skills are essential. Desirable attributes include experience across several therapeutic areas and modalities, familiarity with ICH/GLP standards, and a track record